MENU
+Compare
SYNB
ETF ticker: NYSE ARCA
AS OF
Jan 17 closing price
Price
$30.11
Change
-$0.00 (-0.00%)
Net Assets
5.27M

SYNB stock forecast, quote, news & analysis

Category: @Health
SYNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SYNB with price predictions
Jan 08, 2025

SYNB sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for SYNB moved below the 200-day moving average on December 24, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SYNB entered a downward trend on January 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SYNB's RSI Indicator exited the oversold zone, of 7 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 28 cases where SYNB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 07, 2025. You may want to consider a long position or call options on SYNB as a result. In of 38 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SYNB just turned positive on January 07, 2025. Looking at past instances where SYNB's MACD turned positive, the stock continued to rise in of 17 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SYNB advanced for three days, in of 157 cases, the price rose further within the following month. The odds of a continued upward trend are .

SYNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Alphabet (NASDAQ:GOOGL), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), ZOETIS (NYSE:ZTS), Regeneron Pharmaceuticals (NASDAQ:REGN), lululemon athletica (NASDAQ:LULU), DuPont de Nemours (NYSE:DD), Biogen (NASDAQ:BIIB).

Industry description

The investment seeks long term capital appreciation. The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on “biology revolution” companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.

Market Cap

The average market capitalization across the Putnam BioRevolution ETF ETF is 236.83B. The market cap for tickers in the group ranges from 583.14M to 3.37T. NVDA holds the highest valuation in this group at 3.37T. The lowest valued company is LNZA at 583.14M.

High and low price notable news

The average weekly price growth across all stocks in the Putnam BioRevolution ETF ETF was 1%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was -3%. NGVT experienced the highest price growth at 24%, while LLY experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Putnam BioRevolution ETF ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 66
Price Growth Rating: 56
SMR Rating: 71
Profit Risk Rating: 60
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
SYNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Putnam ETF Trus100 FEDERAL STREET
Phone
6177601060
Web
N/A